This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
J&J (JNJ) Seeks FDA Approval for Myeloma Drug Teclistamab
by Zacks Equity Research
J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.
Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RFG
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
by Zacks Equity Research
Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.
Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day
Is Maravai LifeSciences Holdings, Inc. (MRVI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Maravai LifeSciences Holdings, Inc. (MRVI) and Repligen (RGEN) have performed compared to their sector so far this year.
3 Biotech Stocks Worth Adding to Your Portfolio Next Year
by Ekta Bagri
Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.
ChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA Nod
by Zacks Equity Research
ChemoCentryx's (CCXI) Tavneos gives a significant boost to the company, following its FDA approval in ANCA-associated vasculitis. The drug is also being evaluated in other indications.
Biogen's (BIIB) Alzheimer's Disease Drug Gets FDA Fast Track Tag
by Zacks Equity Research
Biogen (BIIB) receives a fast track designation from the FDA for lecanemab to treat Alzheimer's disease.
AstraZeneca's (AZN) Ultomiris sBLA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to AstraZeneca's (AZN) sBLA for Ultomiris for treating adults with generalized myasthenia gravis. A decision is expected in the second quarter of 2022.
Lilly's (LLY) Eczema Study on Lebrikizumab Combo Meets Goal
by Zacks Equity Research
Eli Lilly's (LLY) pivotal phase III study on lebrikizumab in combination with topical corticosteroids meets the primary and key secondary endpoints.
Sanofi (SNY) to Acquire Amunix, Boost Immuno-oncology Pipeline
by Zacks Equity Research
Sanofi (SNY) inks a deal to acquire privately-held Amunix Pharmaceuticals, which will add potentially transformative cancer therapies to its immuno-oncology pipeline.
Repligen (RGEN) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Repligen (RGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Pfizer (PFE) to Test 3-Dose COVID-19 Vaccine Regimen in Kids
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) to evaluate a third, 3 ug dose at least two months after the second dose of Comirnaty in children aged six months to five years for better protection against COVID-19.
bluebird's (BLUE) BLA for CALD Therapy Gets Priority Review
by Zacks Equity Research
bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.
Novavax (NVAX) COVID Jab Gets WHO Nod for Emergency Use Listing
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine gets approval from WHO for emergency use listing. The vaccine is now pre-qualified for supply to numerous countries participating through the COVAX facility.
Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline
by Zacks Equity Research
Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.
Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RFG
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Should Vanguard S&P MidCap 400 Growth ETF (IVOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVOG
Repligen (RGEN) Q3 Earnings and Sales Beat, 2021 View Up
by Zacks Equity Research
Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021. Resultantly, the stock rises.
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 21.88% and 8.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Repligen's (RGEN) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
Repligen (RGEN) beats earnings and sales estimates in the third quarter of 2021.
Repligen (RGEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Repligen's (RGEN) third-quarter earnings call, investor focus is likely to be on the sales performance of its product franchisees - filtration, chromatography, protein and process analytics.